Pap Testing

Advances in Pap Testing for Cervical Cancer Screening

Since the introduction of the pap test over 50 years ago, two key technological advances have raised standards in cervical cancer screening to new levels.

The first major advance came with the introduction of liquid-based cytology. Since we introduced the ThinPrep Pap Test in 1996, invasive cervical cancers in the United States have declined by nearly 30%,1 and the ThinPrep Pap Test has become the most widely used pap test in the U.S.

A second major advance came in 2003, when we introduced the ThinPrep Imaging System with Dual Review. Dual Review improves disease detection by helping cytotechnologists to focus their review on the areas that need it most. With the ThinPrep Pap Test and the ThinPrep Imaging System, your patients can benefit from the most comprehensive, most advanced technology available today.

HPV Vaccine and the Pap Test: Are Both Necessary?

The pap test continues to play a key role in women's cervical healthcare, alongside advancements like HPV testig and the vaccine.

HPV Testing and the Pap Test

For reflex testing to an ASC-US pap test or for co-testing with the pap for women over the age of 30, HPV testing can provide additional information to a pap test.

ASC-US Triage and HPV Co-testing

Reflex testing for human papillomavirus (HPV) infection is now the standard practice for managing patients whose pap tests show atypical squamous cells of undetermined significance (ASC-US).

Managing Unsatisfactory Pap Test Results

Unsatisfactory pap test results can occur due to a variety of factors, but can be prevented in some cases with the use of correct collection devices and techniques. Current guidelines recommend retesting patients with unsatisfactory pap test results within 2 to 4 months.

Clinical Guidelines on Pap Testing

Several professional organizations have issued guidelines on the use of pap testing in light of recent advances such as HPV testing and the HPV vaccine and liquid-based cytology.

Reference

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Database: Incidence – SEER 9 Regs Public-Use, Nov. 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on November 2004 submission.

Privacy | Terms | Sitemap